^
Association details:
| Biomarker: | UGT1A1*28 |
|---|---|
| Cancer: | Colorectal Cancer |
| Regimen: | FOLFIRI (irinotecan + leucovorin calcium + 5-fluorouracil) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
Excerpt:
This randomised phase II trial evaluated the efficacy and safety of the FOLFIRI regimen with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients....The ORR was significantly higher in the HD-FOLFIRI group (67.5 versus 43.6%; p = 0.001 OR: 1.73 [95% CI:1.03-2.93])….Patients with the UGT1A1*1/*1 and *1/*28 genotypes can receive high doses of irinotecan to achieve a more favourable ORR without significant adverse events.
DOI:
10.1038/s41416-018-0348-7
